2024 World Conference on Lung Cancer (WCLC) - Posters-P2.14A.14 A Real-World Multicenter Retrospective Study of Treatment Outcomes with Ipilimumab and Nivolumab in Mesothelioma

P2.14A.14 A Real-World Multicenter Retrospective Study of Treatment Outcomes with Ipilimumab and Nivolumab in Mesothelioma

Back to course

Pdf Summary

This study evaluates the real-world outcomes of using ipilimumab and nivolumab (Ipi/Nivo) in patients with unresectable mesothelioma, comparing it to outcomes from the CheckMate 743 trial. Traditionally, mesothelioma was treated with chemotherapy involving platinum compounds and pemetrexed. CheckMate 743, however, established Ipi/Nivo as the frontline standard.<br /><br />The retrospective study included patients diagnosed between January 1, 2016, and August 30, 2023, who were treated with Ipi/Nivo either as the frontline treatment or after progression on prior therapies. Key outcomes measured included progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (irAEs).<br /><br />For the frontline group, the median PFS was comparable to the trial group (7.93 months vs. 6.8 months), while median OS was slightly shorter (14.83 months vs. 18.1 months). The frontline group showed lower rates of any-grade irAEs and grade 3/4 irAEs compared to the CheckMate 743 trial (44% and 25% vs. 80% and 30%, respectively).<br /><br />The study's outcomes demonstrate the potential benefits of frontline Ipi/Nivo therapy in terms of tolerability, although survival outcomes were slightly less favorable than the trial results. The evident limitations include the small sample size, particularly in the prior line group, and potential selection bias.<br /><br />Future directions entail analyzing a larger dataset to provide more representative results and comparing real-world outcomes with historical controls of chemotherapy alone. Additionally, assessing predictive markers for treatment response could improve patient-tailored treatments.

Asset Subtitle

Kaushal Parikh

Meta Tag

Speaker Kaushal Parikh

Topic Mesothelioma, Thymoma & Other Thoracic Tumors

Keywords

ipilimumab

nivolumab

mesothelioma

CheckMate 743

progression-free survival

overall survival

treatment-related adverse events

frontline therapy

real-world outcomes

predictive markers